In vitro testing is adequate to support OTC availability of vaginal contraceptives -- NDMA.
This article was originally published in The Tan Sheet
Executive Summary
VAGINAL CONTRACEPTIVE IN VITRO TESTING TO SUPPORT OTC STATUS is recommended by the Nonprescription Drug Manufacturers Association. In June 5 comments responding to the Feb. 3 vaginal contraceptive tentative final monograph ("The Tan Sheet" Feb. 6, p. 3), NDMA maintained that "in vitro and selected biologic testing should be the basis, under monograph standards, for OTC availability of vaginal spermicides."